<DOC>
	<DOCNO>NCT01959269</DOCNO>
	<brief_summary>The purpose study investigate safety effectiveness Stivarga patient metastatic colorectal carcinoma routine use Germany . The study purely observational , data routine treatment collect . The treatment treatment condition solely discretion treat physician .</brief_summary>
	<brief_title>Investigating Use Regorafenib ( Stivarga® ) Patients With Metastatic Colorectal Cancer ( mCRC ) After Failure Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>´ Male female patient ≥ 18 year age metastatic CRC decision take investigator treat Stivarga . Patients must sign informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>